NCT03464045View on ClinicalTrials.gov

Empa PASS on Urinary Tract Malignancies

CompletedOBSERVATIONAL
Enrollment

344,995

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

empagliflozin

empagliflozin

DRUG

DPP-4 inhibitors

DPP-4 inhibitors

Trial Locations (3)

Unknown

The National Register Data, Helsinki

The Swedish prescribed drug register, Stockholm

United Kingdom Clinical Practice Research Datalink (CPRD), London

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY